A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma

NCT04211012 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Urothelial Carcinoma

Interventions

DRUG: Toripalimab plus Nab-Paclitaxel +/- cisplatin

Sponsor

Jun Guo